Home / News / XenoGesis expands into US Market

XenoGesis expands into US Market

Nottingham (UK)-based Contract Research Organisation (CRO) XenoGesis has appointed Sabrina Mogle as a consultant to spearhead US business development strategy, industry awareness and growth efforts.

Sabrina has extensive experience in business and corporate development and strategy having spent her entire career in the biotechnology and pharmaceutical industry. With over 12 years of experience she has gained a wealth of knowledge and understanding of drug development and regulatory affairs in both US and Europe.

Sabrina spent the first half of her career in Contract Research starting in discovery immunology, working with large molecules and therapeutics. She then moved into the small molecule arena focusing on ADME and Toxicology. In more recent roles she has focused on Regulatory Affairs strategies and submissions for rare diseases and oncology.

Sabrina is also co-founder and CEO of RareMoon Consulting, a boutique consulting firm specialising in nonclinical development and regulatory affairs exclusively for orphan products, and works closely with biotechnology executives on their preclinical drug development and regulatory strategies.
Sabrina earned her Bachelor’s Degree in Molecular Biology from the University of Pittsburgh in 2004.

Commenting, Managing Director, Richard Weaver said, “Sabrina’s appointment supports our growth strategy to open up the US market. We already have a number of clients in the US and have identified the opportunity to grow our business further in the US. We are excited to welcome Sabrina to the team and her experience, knowledge and understanding of drug development and regulatory affairs in the US will be a valuable addition to our business. Being based in East Coast area, Sabrina will be developing new business opportunities for XenoGesis using her extensive network of contacts.“

Sabrina added, “XenoGesis is an exciting, fast-growing and ambitious business and is developing an enviable reputation in the preclinical DMPK space for its consultative approach with clients. I am delighted to be part of the team and play my part in supporting the next stage of growth. The US provides a hotbed of opportunities for XenoGesis and I am focusing on identifying new opportunities as well as raising awareness and the profile of the business in the US market.”

XenoGesis will be attending these upcoming events being held in Boston: ‘New England Drug Metabolism Discussion Group Meeting’ and the ISSX Workshop –  ‘Translating Preclinical Data to Human Clearance and Pharmacokinetics’.

For further information, please contact Sue Carr by email or call 07809 727 533, to visit XenoGesis Ltd website click here.

Check Also

Quotient Sciences Constructs State-of-the-Art Early-Phase Formulation and Manufacturing Facility in U.S.

Quotient Sciences, a leading drug development services organisation, announces a significant expansion to its operations …